Medical Malpractice Payouts Data – Insights Hiding in Plain Sight
TL;DR
- •The NPDB recorded $4.7 billion in malpractice payouts in 2023. The mean was $150,000 above the median — a gap that reflects a small number of catastrophic cases pulling the average up, and firms that know how to find them.
- •The risk runs both ways. Firms miss seven-figure cases because the intake review was too shallow to find the breach. Firms also sink $200,000 into cases a matched specialist would have flagged as defensible in a week.
- •The firms consistently recovering on the right side of the distribution aren't doing anything exotic. They treat early specialist review as a strategic decision, not a formality.
· · Article
The National Practitioner Database (NPDB) recorded roughly $4.7 billion in medical malpractice payouts in 2023. The median was around $250,000. The mean was closer to $400,000. That $150,000 difference is not a rounding error — it is the distance between a viable practice and one suffering “successful” outcomes on cases that shouldn’t have been taken in the first place.
What The Standard Distribution Tells Us
A mean that runs $150,000 above the median signals a right-skewed distribution: most cases settle or receive a verdict award toward the bottom, while a relatively small number of catastrophic-harm cases pull the average up. These are the windfall cases that can float a plaintiff firm through months-to-years of lean times. They are also the cases that require the strongest clinical foundation from the start.
Risk Exists on Both Sides of the Equation
The problem amounts to a version of differentiating signal from noise. With the wrong experts, finding “signal” where there is none (ie, false positives) can be costly, while missing signal (ie, false negatives) can result in a missed opportunity.
Firms pass on cases that later settle for seven figures because the intake review was too superficial to find the where liability lies within the fact pattern of the case. A reviewer who lacks depth in the relevant specialty or experience with the procedure or condition in question reads the chart. The expert can see a bad outcome, but often lacks the specific expertise to find the critical breach buried in the documentation.
Firms commonly can also sink $200,000 into discovery on cases a competent physician, reviewing the records before commitment, would have flagged as defensible in a week. That is not a legal failure. It is a clinical intelligence failure — a specialty or practice niche mismatch, a shallow read, a biased screen.
Both scenarios are painful, but for different reasons. Sinking time and money into a case that settles for a paltry sum, or worse results in an unfavorable jury verdict, can be devastating. While seeing a case that your firm passed on settle for a jaw-dropping figure will lead to the sting of regret and judgment from peers and colleagues.
The Fix Is Upstream
The firms that consistently recover on the right side of the distribution of settlements and awards are not doing anything exotic. They simply have developed a sophistication about how and where to invest in rigorous clinical review before meaningful costs are committed. They match specialty to case type rather than using the right expert and not just the one that’s most convenient. And they treat the early review/pre-screen as a non-negotiable strategic decision — not a formality that gets delegated to whoever is available.
If trends hold true, this $4.7 billion figure is likely to be surpassed in coming years. Those funds are waiting to be captured by the firms positioned to understand which cases are worth really going for, and which ones are merely alluring temptations. And the firms who have the greatest success are the ones who invest in solutions that yield the truth about a case’s merit at intake, not at trial.